Home » Stocks » ENVB

Enveric Biosciences, Inc. (ENVB)

Stock Price: $4.30 USD 0.28 (6.97%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $4.34 +0.04 (0.93%) Jan 26, 7:54 PM
Market Cap 54.67M
Revenue (ttm) 35.41M
Net Income (ttm) -7.28M
Shares Out 1.32M
EPS (ttm) -9.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $4.30
Previous Close $4.02
Change ($) 0.28
Change (%) 6.97%
Day's Open 4.10
Day's Range 4.03 - 4.41
Day's Volume 2,363,599
52-Week Range 2.62 - 14.80

News

Hide News
PRNewsWire - 5 days ago

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

PRNewsWire - 1 week ago

NAPLES, Fla., Jan. 15, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines ...

PRNewsWire - 3 weeks ago

NAPLES, Fla., Dec. 31, 2020 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), formerly AMERI Holdings, Inc. (NASDAQ: AMRH), a patient-centric biotechnology...

Other stocks mentioned: AMRH

About ENVB

Jay Pharma develops evidence-based cannabinoid products and combination therapies cure effects of cancer treatment. The company was incorporated in 2017 and is based in Toronto, Canada.

Industry
Biotechnology
Founded
1994
CEO
Brent Kelton
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
ENVB
Full Company Profile

Financial Performance

In 2019, ENVB's revenue was $39.91 million, a decrease of -7.17% compared to the previous year's $43.00 million. Losses were -$5.61 million, -66.81% less than in 2018.

Financial Statements